PCRX vs. SUPN, ALXO, AGIO, ADCT, AVIR, NKTR, MCRB, CORT, ALKS, and PRGO
Should you be buying Pacira BioSciences stock or one of its competitors? The main competitors of Pacira BioSciences include Supernus Pharmaceuticals (SUPN), ALX Oncology (ALXO), Agios Pharmaceuticals (AGIO), ADC Therapeutics (ADCT), Atea Pharmaceuticals (AVIR), Nektar Therapeutics (NKTR), Seres Therapeutics (MCRB), Corcept Therapeutics (CORT), Alkermes (ALKS), and Perrigo (PRGO). These companies are all part of the "pharmaceutical preparations" industry.
Supernus Pharmaceuticals (NASDAQ:SUPN) and Pacira BioSciences (NASDAQ:PCRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, community ranking, earnings, dividends, media sentiment, valuation, profitability and institutional ownership.
Pacira BioSciences has higher revenue and earnings than Supernus Pharmaceuticals.
Supernus Pharmaceuticals has a beta of 0.99, meaning that its share price is 1% less volatile than the S&P 500. Comparatively, Pacira BioSciences has a beta of 0.76, meaning that its share price is 24% less volatile than the S&P 500.
99.7% of Pacira BioSciences shares are held by institutional investors. 8.8% of Supernus Pharmaceuticals shares are held by insiders. Comparatively, 6.6% of Pacira BioSciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
In the previous week, Pacira BioSciences had 2 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 6 mentions for Pacira BioSciences and 4 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.95 beat Pacira BioSciences' score of 0.42 indicating that Pacira BioSciences is being referred to more favorably in the news media.
Pacira BioSciences has a net margin of 6.22% compared to Pacira BioSciences' net margin of 0.22%. Supernus Pharmaceuticals' return on equity of 12.81% beat Pacira BioSciences' return on equity.
Supernus Pharmaceuticals presently has a consensus target price of $41.00, indicating a potential upside of 35.40%. Pacira BioSciences has a consensus target price of $49.50, indicating a potential upside of 90.31%. Given Supernus Pharmaceuticals' higher probable upside, analysts plainly believe Pacira BioSciences is more favorable than Supernus Pharmaceuticals.
Pacira BioSciences received 336 more outperform votes than Supernus Pharmaceuticals when rated by MarketBeat users. However, 73.25% of users gave Supernus Pharmaceuticals an outperform vote while only 71.73% of users gave Pacira BioSciences an outperform vote.
Summary
Pacira BioSciences beats Supernus Pharmaceuticals on 11 of the 15 factors compared between the two stocks.
Get Pacira BioSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for PCRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding PCRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Pacira BioSciences Competitors List
Related Companies and Tools
